Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in systemic sclerosis
NCT05214794Phase 2Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Apr 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nemolizumab in systemic sclerosis (SSc), sponsored by Maruho Co., Ltd. Primary endpoint: Modified Rodnan Total Skin Thickness at 24 weeks. Started Apr 2022; status: completed.
02
Drugs
nemolizumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT05214794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05214794.